{
"info": {
"nct_id": "NCT00089427",
"official_title": "Phase I Study of Convection Enhanced Delivery (CED) of IL13-PE38QQR Infusion After Resection Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Supratentorial Malignant Glioma",
"inclusion_criteria": "* Patients must be ≥18 years old.\n* Patients must have undergone a gross total resection of the solid contrast-enhancing lesion(s) > 1.0 cm in diameter.\n* Patients must be able to have catheters placed within 14 days of tumor resection (including a planned Gross Total Resection following an initial biopsy or subtotal resection)\n* Patients must have histopathologic confirmation of malignant glioma from resection specimen. Diagnosis must be consistent with either GBM, AA, or malignant mixed OA.\n* Patients must be in adequate general condition and meet the following criteria:\n* a. Karnofsky Performance Scale score ≥ 70\n* b. Adequate hematologic status:\n\n * Absolute neutrophil count ≥ 1,500/mm³\n * Hemoglobin ≥ 10 gm/dL\n * Platelets ≥ 100,000/mm³\n * PT & aPTT within institutional limits of normal\n* Female patients must not be pregnant or breast-feeding.\n* Patients must practice an effective method of birth control during the study and for 60 days beyond the last day of infusion.\n* Patients must understand the investigational nature of this study and its potential risks and benefits, and sign an approved written informed consent prior to performance of any study-specific procedure.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Patients with residual contrast-enhancing tumor crossing the midline, multifocal tumor not amenable to gross total resection or non-parenchymal tumor dissemination (e.g., subependymal or leptomeningeal).\n* Patients with clinically significant increased ICP (e.g., impending herniation), uncontrolled seizures or requirement for immediate palliative treatment.\n* Patients who have received any prior anti-tumor treatment (other than corticosteroids) including any investigational agents.\n* Patients with any metallic prosthesis that would prevent MRI and/or MRS scanning procedures of the brain.\n* Patients unwilling or unable to follow protocol requirements.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patients must be ≥18 years old.",
"criterions": [
{
"exact_snippets": "Patients must be ≥18 years old.",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Patients must have undergone a gross total resection of the solid contrast-enhancing lesion(s) > 1.0 cm in diameter.",
"criterions": [
{
"exact_snippets": "undergone a gross total resection of the solid contrast-enhancing lesion(s)",
"criterion": "gross total resection of solid contrast-enhancing lesion(s)",
"requirements": [
{
"requirement_type": "completion",
"expected_value": true
}
]
},
{
"exact_snippets": "lesion(s) > 1.0 cm in diameter",
"criterion": "lesion size",
"requirements": [
{
"requirement_type": "size",
"expected_value": {
"operator": ">",
"value": 1.0,
"unit": "cm"
}
}
]
}
]
},
{
"line": "* Patients must be able to have catheters placed within 14 days of tumor resection (including a planned Gross Total Resection following an initial biopsy or subtotal resection)",
"criterions": [
{
"exact_snippets": "Patients must be able to have catheters placed",
"criterion": "catheter placement ability",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
},
{
"exact_snippets": "within 14 days of tumor resection",
"criterion": "catheter placement timing",
"requirements": [
{
"requirement_type": "timing",
"expected_value": {
"operator": "<=",
"value": 14,
"unit": "days"
}
}
]
}
]
},
{
"line": "* Patients must have histopathologic confirmation of malignant glioma from resection specimen. Diagnosis must be consistent with either GBM, AA, or malignant mixed OA.",
"criterions": [
{
"exact_snippets": "histopathologic confirmation of malignant glioma",
"criterion": "malignant glioma",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": true
}
]
},
{
"exact_snippets": "Diagnosis must be consistent with either GBM, AA, or malignant mixed OA",
"criterion": "diagnosis consistency",
"requirements": [
{
"requirement_type": "consistency",
"expected_value": [
"GBM",
"AA",
"malignant mixed OA"
]
}
]
}
]
},
{
"line": "* Patients must be in adequate general condition and meet the following criteria:",
"criterions": [
{
"exact_snippets": "adequate general condition",
"criterion": "general condition",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* a. Karnofsky Performance Scale score ≥ 70",
"criterions": [
{
"exact_snippets": "Karnofsky Performance Scale score ≥ 70",
"criterion": "Karnofsky Performance Scale score",
"requirements": [
{
"requirement_type": "score",
"expected_value": {
"operator": ">=",
"value": 70,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* b. Adequate hematologic status:",
"criterions": [
{
"exact_snippets": "Adequate hematologic status",
"criterion": "hematologic status",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Absolute neutrophil count ≥ 1,500/mm³",
"criterions": [
{
"exact_snippets": "Absolute neutrophil count ≥ 1,500/mm³",
"criterion": "absolute neutrophil count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1500,
"unit": "mm³"
}
}
]
}
]
},
{
"line": "* Hemoglobin ≥ 10 gm/dL",
"criterions": [
{
"exact_snippets": "Hemoglobin ≥ 10 gm/dL",
"criterion": "hemoglobin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 10,
"unit": "gm/dL"
}
}
]
}
]
},
{
"line": "* Platelets ≥ 100,000/mm³",
"criterions": [
{
"exact_snippets": "Platelets ≥ 100,000/mm³",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 100000,
"unit": "mm³"
}
}
]
}
]
},
{
"line": "* PT & aPTT within institutional limits of normal",
"criterions": [
{
"exact_snippets": "PT ... within institutional limits of normal",
"criterion": "PT",
"requirements": [
{
"requirement_type": "range",
"expected_value": "within institutional limits of normal"
}
]
},
{
"exact_snippets": "aPTT within institutional limits of normal",
"criterion": "aPTT",
"requirements": [
{
"requirement_type": "range",
"expected_value": "within institutional limits of normal"
}
]
}
]
},
{
"line": "* Female patients must not be pregnant or breast-feeding.",
"criterions": [
{
"exact_snippets": "Female patients must not be pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Female patients must not be ... breast-feeding",
"criterion": "breast-feeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients must practice an effective method of birth control during the study and for 60 days beyond the last day of infusion.",
"criterions": [
{
"exact_snippets": "Patients must practice an effective method of birth control",
"criterion": "birth control",
"requirements": [
{
"requirement_type": "practice",
"expected_value": true
}
]
},
{
"exact_snippets": "during the study and for 60 days beyond the last day of infusion",
"criterion": "duration of birth control",
"requirements": [
{
"requirement_type": "duration",
"expected_value": "during the study and for 60 days beyond the last day of infusion"
}
]
}
]
},
{
"line": "* Patients must understand the investigational nature of this study and its potential risks and benefits, and sign an approved written informed consent prior to performance of any study-specific procedure.",
"criterions": [
{
"exact_snippets": "Patients must understand the investigational nature of this study and its potential risks and benefits",
"criterion": "understanding of study nature and risks/benefits",
"requirements": [
{
"requirement_type": "understanding",
"expected_value": true
}
]
},
{
"exact_snippets": "sign an approved written informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "signed",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Patients with residual contrast-enhancing tumor crossing the midline, multifocal tumor not amenable to gross total resection or non-parenchymal tumor dissemination (e.g., subependymal or leptomeningeal).",
"criterions": [
{
"exact_snippets": "residual contrast-enhancing tumor crossing the midline",
"criterion": "residual contrast-enhancing tumor crossing the midline",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "multifocal tumor not amenable to gross total resection",
"criterion": "multifocal tumor",
"requirements": [
{
"requirement_type": "amenability to gross total resection",
"expected_value": false
}
]
},
{
"exact_snippets": "non-parenchymal tumor dissemination (e.g., subependymal or leptomeningeal)",
"criterion": "non-parenchymal tumor dissemination",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients with clinically significant increased ICP (e.g., impending herniation), uncontrolled seizures or requirement for immediate palliative treatment.",
"criterions": [
{
"exact_snippets": "clinically significant increased ICP",
"criterion": "increased intracranial pressure (ICP)",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "clinically significant"
}
]
},
{
"exact_snippets": "uncontrolled seizures",
"criterion": "seizures",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
}
]
},
{
"exact_snippets": "requirement for immediate palliative treatment",
"criterion": "palliative treatment",
"requirements": [
{
"requirement_type": "urgency",
"expected_value": "immediate"
}
]
}
]
},
{
"line": "* Patients who have received any prior anti-tumor treatment (other than corticosteroids) including any investigational agents.",
"criterions": [
{
"exact_snippets": "Patients who have received any prior anti-tumor treatment (other than corticosteroids)",
"criterion": "prior anti-tumor treatment",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "including any investigational agents",
"criterion": "prior investigational agents",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients with any metallic prosthesis that would prevent MRI and/or MRS scanning procedures of the brain.",
"criterions": [
{
"exact_snippets": "any metallic prosthesis that would prevent MRI and/or MRS scanning procedures of the brain",
"criterion": "metallic prosthesis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients unwilling or unable to follow protocol requirements.",
"criterions": [
{
"exact_snippets": "Patients unwilling ... to follow protocol requirements.",
"criterion": "willingness to follow protocol requirements",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
}
]
},
{
"exact_snippets": "Patients ... unable to follow protocol requirements.",
"criterion": "ability to follow protocol requirements",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}